Trial Profile

Pharmacokinetic/Pharmacodynamic Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teneligliptin (Primary)
Indications Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Sponsors Mitsubishi Tanabe Pharma Corporation

Most Recent Events

01 Nov 2012 Primary endpoint '2 hour postprandial glucose level' has been met according to results published in the Diabetes, Obesity and Metabolism.
01 Nov 2012 Results published in the Diabetes, Obesity and Metabolism.
04 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com